[Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
A 51-year-old woman, who presented with dyspnea on effort and was diagnosed with autoimmune hemolytic anemia in July 2004, was suspected of having splenic marginal zone lymphoma (SMZL) because of clonality of B cell on bone marrow and splenomegaly. She underwent splenectomy, and histopathological examination of the resected specimen confirmed the diagnosis of SMZL. The patient was treated with rituximab, and complete remission was achieved. Up to the present, three years after diagnosis, the patient has shown no evidence of progression.
Miztani
Minoru
M
Department of Internal Medicine, Yamada Red Cross Hospital.
Noda
Tomohiro
T
Umino
Akira
A
Tanigawa
Motoaki
M
Taniguchi
Masanori
M
Tamaki
Shigehisa
S
Tsuji
Kouta
K
D000744:Anemia, Hemolytic, Autoimmune / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D000069283:Rituximab; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000473:pathology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab